Show simple item record

dc.contributor.authorGelincik, Aslı et al.
dc.description.abstractCoronavirus disease 2019 (COVID‐19), a respiratory tract infection caused by a novel human coronavirus, the severe acute respiratory syndrome coronavirus 2, leads to a wide spectrum of clinical manifestations ranging from asymptomatic cases to patients with mild and severe symptoms, with or without pneumonia. Given the huge influence caused by the overwhelming COVID‐19 pandemic affecting over three million people worldwide, a wide spectrum of drugs is considered for the treatment in the concept of repurposing and off‐label use. There is no knowledge about the diagnosis and clinical management of the drug hypersensitivity reactions that can potentially occur during the disease. This review brings togetherall the published information about the diagnosis and management of drug hypersensitivity reactions due to current and candidate off‐label drugs andhighlights relevant recommendations. Furthermore, it gathers all the dermatologic manifestations reported during the disease for guiding the clinicians to establish a better differential diagnosis of drug hypersensitivity reactionsin the course of the disease.en_US
dc.subjectInfectious Diseasesen_US
dc.subjectDesensitization, Immunologicen_US
dc.subjectDrug Hypersensitivityen_US
dc.titleDiagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19en_US
eihealth.categoryCandidate therapeutics RDen_US
eihealth.typeOther publicationsen_US
eihealth.maincategorySave Lives / Salvar Vidasen_US

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record